- Home
- NSP vs CGON Comparison
NSP vs CGON Comparison
Compare NSP & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSP
- CGON
- Stock Information
- Founded
- NSP 1986
- CGON 2010
- Country
- NSP United States
- CGON United States
- Employees
- NSP N/A
- CGON N/A
- Industry
- NSP Professional Services
- CGON
- Sector
- NSP Consumer Discretionary
- CGON
- Exchange
- NSP Nasdaq
- CGON NYSE
- Market Cap
- NSP 2.6B
- CGON 2.3B
- IPO Year
- NSP 1997
- CGON 2024
- Fundamental
- Price
- NSP $84.90
- CGON $27.85
- Analyst Decision
- NSP Hold
- CGON Strong Buy
- Analyst Count
- NSP 4
- CGON 10
- Target Price
- NSP $95.67
- CGON $65.11
- AVG Volume (30 Days)
- NSP 471.3K
- CGON 421.1K
- Earning Date
- NSP 02-10-2025
- CGON 03-04-2025
- Dividend Yield
- NSP 2.83%
- CGON N/A
- EPS Growth
- NSP N/A
- CGON N/A
- EPS
- NSP 2.39
- CGON N/A
- Revenue
- NSP $6,581,000,000.00
- CGON $684,000.00
- Revenue This Year
- NSP $5.91
- CGON $210.00
- Revenue Next Year
- NSP $7.79
- CGON N/A
- P/E Ratio
- NSP $35.45
- CGON N/A
- Revenue Growth
- NSP 1.46
- CGON 258.12
- 52 Week Low
- NSP $68.79
- CGON $25.77
- 52 Week High
- NSP $110.72
- CGON $48.05
- Technical
- Relative Strength Index (RSI)
- NSP 58.80
- CGON 41.49
- Support Level
- NSP $85.48
- CGON $27.10
- Resistance Level
- NSP $88.19
- CGON $29.42
- Average True Range (ATR)
- NSP 3.30
- CGON 1.15
- MACD
- NSP 0.92
- CGON -0.10
- Stochastic Oscillator
- NSP 83.04
- CGON 29.02
About NSP Insperity Inc.
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.